Tag: Us healthcare

The average cash price for a 30-day supply of Rexulti (brexpiprazole) can range from $1,800 to over $2,000 without insurance. Understanding **how much is Rexulti in the US** is not straightforward, as the out-of-pocket cost varies widely depending on your insurance coverage, dosage, and access to savings programs.

The estimated cost for treatment with enfortumab vedotin (Padcev) is approximately $17,718 per 28-day cycle [1.2.2]. This article explores the question, 'How much does enfortumab vedotin cost in the US?', by examining pricing, influencing factors, and financial support systems.

Despite being used in many countries for decades to treat angina, trimetazidine has never been approved by the US Food and Drug Administration (FDA). This article delves into the critical factors, including strict safety and efficacy requirements, that explain why is trimetazidine not used in the US.

Used widely in Japan, China, and several South American countries for gastrointestinal motility issues, mosapride is not approved for clinical use in the United States. For individuals suffering from gastroparesis or functional dyspepsia, understanding why **is mosapride available in the US** is a crucial first step in finding effective treatment within the U.S. healthcare system.

Cinnarizine is not approved for marketing in the United States by the U.S. Food and Drug Administration (FDA), making it unavailable to American consumers [1.2.2, 1.3.2]. The answer to **why is cinnarizine not available in the US?** involves its dual properties as an antihistamine and a calcium channel blocker, along with concerns about potential side effects [1.2.1, 1.3.4].

Ambroxol is a common over-the-counter mucolytic medication used widely across Europe and other countries for over three decades to treat respiratory illnesses. However, despite its long history of safe use abroad, the mucolytic agent Ambroxol is not available in the USA due to a combination of regulatory requirements and market dynamics.

Recent data reveals that Kentucky has the highest rate of prescriptions for GLP-1 drugs like Ozempic, with 20.7 prescriptions per 1,000 people [1.2.1, 1.2.3, 1.2.9]. This article explores what state uses the most Ozempic and the underlying factors driving these trends.

Despite its availability in countries like Canada, the UK, and Australia for treating abdominal cramps, many wonder: Why is Buscopan no longer available in the US? [1.2.2, 1.2.5]. The straightforward answer is that its active ingredient, hyoscine butylbromide, lacks approval from the U.S. Food and Drug Administration (FDA) for human use [1.2.1, 1.3.1, 1.3.3].

Oral Rehydration Solution (ORS) is a medical innovation credited with saving millions of lives globally, particularly in situations involving diarrheal diseases. In America, while the medical term ORS is used, the treatment is more often identified by specific brand names and the descriptive phrase "oral rehydration solution," with products available for both adults and children.